Stockscreener 앱 받기
76.74
1.03%
0.78
Ptc Therapeutics Inc 주식(PTCT)의 최신 뉴스
PTC Therapeutics (NASDAQ:PTCT) Upgraded to Buy at Wall Street Zen - MarketBeat
Matthew Klein Sells 8,089 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Behavioral Patterns of PTCT and Institutional Flows - Stock Traders Daily
What's Going On With Royalty Pharma Stock Wednesday? - Benzinga
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Reach - openPR.com
Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics - Nasdaq
Royalty Pharma Acquires Final Portion of Evrysdi Royalty from PTC Therapeutics for $240 Million - Quiver Quantitative
PTC Therapeutics Fully Monetizes Evrysdi Royalty Interest - TipRanks
PTC Therapeutics Signs Royalty Purchase Agreement Amendment With Royalty Pharma - TradingView — Track All Markets
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? - AOL.com
Pacer Advisors Inc. Has $30.93 Million Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
PTC Therapeutics Earnings Notes - Trefis
PTC Therapeutics (NASDAQ:PTCT) Insider Eric Pauwels Sells 20,508 Shares of Stock - MarketBeat
PTC Therapeutics Executive Eric Pauwels Sells Over 20,000 Shares - TradingView — Track All Markets
Director Reeve Emma exercised 733 shares at a strike of $46.54 and sold $57,628 worth of shares (733 units at $78.62) (SEC Form 4) - Quantisnow
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan - Sahm
Japan Sephience Approval Could Be A Game Changer For PTC Therapeutics’ (PTCT) Rare-Disease Strategy - Yahoo Finance
PTC Therapeutics (PTCT): Valuation Check After First Japan Approval Completes Global Sephience Launch - Yahoo Finance
(PTCT) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) - GuruFocus
PTC Therapeutics' Phenylketonuria Treatment Approved in Japan - marketscreener.com
PTC Therapeutics receives Japan approval for PKU treatment Sephience By Investing.com - Investing.com Nigeria
Voya Investment Management LLC Has $17.48 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTCT Gains Japanese Approval for Phenylketonuria Treatment - GuruFocus
PTC Therapeutics receives Japan approval for PKU treatment Sephience - Investing.com
PTC Therapeutics, Inc. $PTCT Shares Sold by Assenagon Asset Management S.A. - MarketBeat
PTC Therapeutics Shares Drop After FDA Rejects Vatiquinone Application - MSN
Assessing PTC Therapeutics (PTCT) Valuation After Health Canada’s Sephience Approval Expands PKU Market Potential - Sahm
EPS Watch: Why millennials buy PTC Therapeutics Inc. (BH3) stock2025 Winners & Losers & Short-Term Swing Trade Alerts - ulpravda.ru
PTC Therapeutics (PTCT) Gets a Buy from Wells Fargo - The Globe and Mail
Will PTC Therapeutics Inc. stock attract more institutional investors2025 Trading Volume Trends & Accurate Buy Signal Notifications - Улправда
Insider Sell Alert: Eric Pauwels Sells 43,492 Shares of PTC Ther - GuruFocus
Eric Pauwels Sells 3,202 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics Executive Eric Pauwels Sells Over $3 Million in Company Stock - TradingView — Track All Markets
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
Officer Pauwels Files To Sell 20,508 Of PTC Therapeutics Inc [PTCT] - TradingView — Track All Markets
Is PTC Therapeutics Inc. stock supported by innovation pipelineMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - Улправда
Is PTC Therapeutics Inc. (BH3) stock undervalued by metricsQuarterly Portfolio Report & Free Reliable Trade Execution Plans - Улправда
Why PTC Therapeutics Inc. stock remains resilient2025 Price Momentum & Daily Volume Surge Trade Alerts - DonanımHaber
Is PTC Therapeutics Inc. stock a defensive play in 2025Market Performance Summary & Low Drawdown Momentum Ideas - DonanımHaber
Aug Catalysts: Is PTC Therapeutics Inc. (BH3) stock undervalued by metrics2025 Investor Takeaways & Real-Time Volume Spike Alerts - ulpravda.ru
PTC Therapeutics (PTCT) director exercises stock option, now holds 155,266 shares - Stock Titan
Why hedge funds are buying PTC Therapeutics Inc. stockJuly 2025 Technicals & Fast Entry and Exit Trade Plans - Улправда
PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healt - GuruFocus
PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Nasdaq
Officer Pauwels Files To Sell 40,290 Of PTC Therapeutics Inc [PTCT] - TradingView — Track All Markets
PTC Therapeutics (PTCT) Is Down 9.5% After Broad S&P Additions And Insider Moves Has The Bull Case Changed? - Sahm
PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - Quantisnow
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2025 Earnings Call Transcript - MSN
Squarepoint Ops LLC Grows Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76 - MSN
Armistice Capital LLC Has $231.28 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT): Revisiting Valuation After a Strong Multi‑Year Share Price Run - Sahm
PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) – Company Announcement - Financial Times
Marshall Wace LLP Reduces Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT Stock Position Raised by Hood River Capital Management LLC - MarketBeat
PTC Therapeutics (PTCT) Price Target Increased by 15.54% to 80.45 - MSN
0.57%
자본화:
|
볼륨(24시간):